BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang X, Miao X, Sun T, Tan W, Qu S, Xiong P, Zhou Y, Lin D. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 2005;42:479-84. [PMID: 15937082 DOI: 10.1136/jmg.2004.030106] [Cited by in Crossref: 102] [Cited by in F6Publishing: 95] [Article Influence: 6.4] [Reference Citation Analysis]
Number Citing Articles
1 Guo XY, Xia YL, Li ZY, Li R, Fan Y, Yao WM, Liu F. Fas -670 A/G polymorphism predicts prognosis of hepatocellular carcinoma after curative resection in Chinese Han population. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00123-5. [PMID: 34366198 DOI: 10.1016/j.hbpd.2021.07.001] [Reference Citation Analysis]
2 Annuar AA, Ankathil R, Mohd Yunus N, Husin A, Ab Rajab NS, Abdul Aziz AA, Ibrahim MI, Sulong S. Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients. Asian Pac J Cancer Prev 2021;22:565-71. [PMID: 33639675 DOI: 10.31557/APJCP.2021.22.2.565] [Reference Citation Analysis]
3 Zhao T, Li W, Chen J, Qin W. Genomic variants in Fas-mediated apoptosis pathway predict a poor response to Platinum-based Chemotherapy for Chinese Gastric Cancer Patients. J Cancer 2021;12:849-59. [PMID: 33403042 DOI: 10.7150/jca.48120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Costa EFD, Lima TRP, Lopes-Aguiar L, Nogueira GAS, Visacri MB, Quintanilha JCF, Pincinato EC, Calonga L, Mariano FV, Altemani AMAM, Altemani JMC, Moriel P, Chone CT, Ramos CD, Lima CSP. FAS and FASL variations in outcomes of tobacco- and alcohol-related head and neck squamous cell carcinoma patients. Tumour Biol 2020;42:1010428320938494. [PMID: 32628088 DOI: 10.1177/1010428320938494] [Reference Citation Analysis]
5 Strizova Z, Snajdauf M, Stakheev D, Taborska P, Vachtenheim J Jr, Biskup J, Lischke R, Bartunkova J, Smrz D. The paratumoral immune cell signature reveals the potential for the implementation of immunotherapy in esophageal carcinoma patients. J Cancer Res Clin Oncol 2020;146:1979-92. [PMID: 32447483 DOI: 10.1007/s00432-020-03258-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wan Mohd Tajuddin WNB, Lajis NH, Abas F, Othman I, Naidu R. Mechanistic Understanding of Curcumin's Therapeutic Effects in Lung Cancer. Nutrients 2019;11:E2989. [PMID: 31817718 DOI: 10.3390/nu11122989] [Cited by in Crossref: 15] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
7 Coco S, Bonfiglio S, Cittaro D, Vanni I, Mora M, Genova C, Dal Bello MG, Boccardo S, Alama A, Rijavec E, Sini C, Rossella V, Barletta G, Biello F, Truini A, Bruzzo C, Gallo M, Lazarevic D, Ballestrero A, Grossi F. Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer. Cancers (Basel) 2019;11:E441. [PMID: 30925779 DOI: 10.3390/cancers11040441] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Wang J, Liao AM, Thakur K, Zhang JG, Huang JH, Wei ZJ. Licochalcone B Extracted from Glycyrrhiza uralensis Fisch Induces Apoptotic Effects in Human Hepatoma Cell HepG2. J Agric Food Chem 2019;67:3341-53. [PMID: 30835110 DOI: 10.1021/acs.jafc.9b00324] [Cited by in Crossref: 32] [Cited by in F6Publishing: 40] [Article Influence: 10.7] [Reference Citation Analysis]
9 Chakravarti N, Ivan D, Trinh VA, Glitza IC, Curry JL, Torres-Cabala C, Tetzlaff MT, Bassett RL, Prieto VG, Hwu WJ. High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients. Melanoma Res 2017;27:24-31. [PMID: 27768639 DOI: 10.1097/CMR.0000000000000305] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
10 Sun Y, Li J, Zheng C, Zhou B. Study on polymorphisms in CHRNA5/CHRNA3/CHRNB4 gene cluster and the associated with the risk of non-small cell lung cancer. Oncotarget 2018;9:2435-44. [PMID: 29416783 DOI: 10.18632/oncotarget.23459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
11 Carron J, Lopes-aguiar L, Costa EFD, Nogueira GAS, Lima TRP, Pincinato EC, Visacri MB, Quintanilha JCF, Moriel P, Lourenço GJ, Lima CSP. GSTP1 c.313A>G, XPD c.934G>A, XPF c.2505T>C and CASP9 c.-1339A>G Polymorphisms and Severity of Vomiting in Head and Neck Cancer Patients treated with Cisplatin Chemoradiation. Basic Clin Pharmacol Toxicol 2017;121:520-5. [DOI: 10.1111/bcpt.12842] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
12 Anlar HG, Bacanli M, İritaş S, Bal C, Kurt T, Tutkun E, Hinc Yilmaz O, Basaran N. Effects of Occupational Silica Exposure on OXIDATIVE Stress and Immune System Parameters in Ceramic Workers in TURKEY. Journal of Toxicology and Environmental Health, Part A 2017;80:688-96. [DOI: 10.1080/15287394.2017.1286923] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
13 Lin J, Zhang Y, Wang H, Chang J, Wei L, Cao L, Zhang Z, Zhang X. Genetic Polymorphisms in the Apoptosis-Associated Gene CASP3 and the Risk of Lung Cancer in Chinese Population. PLoS One 2016;11:e0164358. [PMID: 27723786 DOI: 10.1371/journal.pone.0164358] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
14 Yu X, Li Y, Yu Y, Lei J, Wan G, Cao F. Associations between FAS rs2234767 and FASL rs763110 polymorphisms and the risk of lung cancer: a meta-analysis of 39,736 subjects. Onco Targets Ther 2016;9:2049-56. [PMID: 27103831 DOI: 10.2147/OTT.S102723] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
15 Zhang M, Wu C, Li B, Du W, Zhang C, Chen Z. Quantitative assessment of the association between Fas/FasL gene polymorphism and susceptibility to esophageal carcinoma in a north Chinese population. Cancer Med 2016;5:760-6. [PMID: 26819081 DOI: 10.1002/cam4.633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
16 Khalifa RH, Bahgat DM, Darwish HA, Shahin RM. Significant association between FasL gene -844T/C polymorphism and risk to hepatocellular carcinoma in Egyptian patients. Immunol Lett. 2016;172:84-88. [PMID: 26891954 DOI: 10.1016/j.imlet.2016.02.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Sun Y, Yu W, Sturgis EM, Peng W, Lei D, Wei Q, Song X, Li G. Site disparities in apoptotic variants as predictors of risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck. BMC Cancer 2016;16:70. [PMID: 26858129 DOI: 10.1186/s12885-016-2110-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 Chattopadhyay K, Williamson AL, Hazra A, Dandara C. The combined risks of reduced or increased function variants in cell death pathway genes differentially influence cervical cancer risk and herpes simplex virus type 2 infection among black Africans and the Mixed Ancestry population of South Africa. BMC Cancer 2015;15:680. [PMID: 26458812 DOI: 10.1186/s12885-015-1678-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
19 Zhang F, Sturgis EM, Sun Y, Zhang Y, Wei Q, Zhang C, Zheng H, Li G. Apoptotic variants as predictors of risk of oropharyngeal cancer recurrence after definitive radiotherapy. Int J Cancer 2015;137:2454-61. [PMID: 25976983 DOI: 10.1002/ijc.29604] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
20 Zhao H, Chen W, Du P, Sun A, Zhuang C, Tong J, Wang L. FasL -844T/C and Fas -1377G/A: mutations of pulmonary adenocarcinoma in South China and their clinical significances. Tumour Biol 2015;36:4319-26. [PMID: 25596086 DOI: 10.1007/s13277-015-3071-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
21 Xu Y, He B, Li R, Pan Y, Gao T, Deng Q, Sun H, Song G, Wang S. Association of the polymorphisms in the Fas/FasL promoter regions with cancer susceptibility: a systematic review and meta-analysis of 52 studies. PLoS One 2014;9:e90090. [PMID: 24598538 DOI: 10.1371/journal.pone.0090090] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
22 Rai R, Sharma KL, Sharma S, Misra S, Kumar A, Mittal B. Death receptor (DR4) haplotypes are associated with increased susceptibility of gallbladder carcinoma in north Indian population. PLoS One 2014;9:e90264. [PMID: 24587306 DOI: 10.1371/journal.pone.0090264] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
23 Wang X, Xing GH, Fan CC. Association between the FAS rs2234767G/A polymorphism and cancer risk: a systematic review and meta-analysis. DNA Cell Biol 2014;33:320-7. [PMID: 24568648 DOI: 10.1089/dna.2013.2273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
24 Geng P, Li J, Ou J, Xie G, Wang N, Xiang L, Sa R, Liu C, Li H, Liang H. Association of Fas -1377 G/A polymorphism with susceptibility to cancer. PLoS One 2014;9:e88748. [PMID: 24558420 DOI: 10.1371/journal.pone.0088748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
25 Zhao H, Zheng L, Li X, Wang L. FasL gene -844T/C mutation of esophageal cancer in South China and its clinical significance. Sci Rep 2014;4:3866. [PMID: 24473454 DOI: 10.1038/srep03866] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
26 Dalan AB, Timirci-kahraman O, Turan S, Kafadar AM, Yaylim I, Ergen A, Gormus U, Gulec-yilmaz S, Kaspar C, Isbir T. Association between FAS and FASL Genetic Variants and Risk of Primary Brain Tumor. International Journal of Neuroscience 2013;124:443-9. [DOI: 10.3109/00207454.2013.850083] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
27 Valibeigi B, Amirghofran Z, Golmoghaddam H, Hajihosseini R, Kamazani FM. Fas gene variants in childhood acute lymphoblastic leukemia and association with prognosis. Pathol Oncol Res 2014;20:367-74. [PMID: 24218069 DOI: 10.1007/s12253-013-9705-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
28 Xu L, Zhou X, Jiang F, Qiu MT, Zhang Z, Yin R, Xu L. FASL rs763110 polymorphism contributes to cancer risk: an updated meta-analysis involving 43,295 subjects. PLoS One. 2013;8:e74543. [PMID: 24086353 DOI: 10.1371/journal.pone.0074543] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
29 Zhong-Xing Z, Yuan-Yuan M, Hai Zhen M, Jian-Gang Z, Li-Feng Z. FAS-1377 G/A (rs2234767) polymorphism and cancer susceptibility: a meta-analysis of 17,858 cases and 24,311 controls. PLoS One 2013;8:e73700. [PMID: 24014103 DOI: 10.1371/journal.pone.0073700] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
30 Han W, Zhou Y, Zhong R, Wu C, Song R, Liu L, Zou L, Qiao Y, Zhai K, Chang J, Huang L, Liu L, Lu X, Lou J, Yu D, Tan W, Zhang J, Wang H, Miao X. Functional polymorphisms in FAS/FASL system increase the risk of neuroblastoma in Chinese population. PLoS One 2013;8:e71656. [PMID: 23951214 DOI: 10.1371/journal.pone.0071656] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
31 Cao L, Lin J, He B, Wang H, Rao J, Liu Y, Zhang X. A regulatory variant in CYP2E1 affects the risk of lung squamous cell carcinoma. Tumor Biol 2014;35:455-62. [DOI: 10.1007/s13277-013-1063-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
32 de Carvalho-Neto PB, dos Santos M, de Carvalho MB, Mercante AM, dos Santos VP, Severino P, Tajara EH, Louro ID, da Silva-Conforti AM. FAS/FASL expression profile as a prognostic marker in squamous cell carcinoma of the oral cavity. PLoS One 2013;8:e69024. [PMID: 23894399 DOI: 10.1371/journal.pone.0069024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
33 Yıldır S, Sezgin M, Barlas İÖ, Türköz G, Ankaralı HÇ, Şahin G, Erdal ME. Relation of the Fas and FasL gene polymorphisms with susceptibility to and severity of rheumatoid arthritis. Rheumatol Int 2013;33:2637-45. [DOI: 10.1007/s00296-013-2793-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
34 Pan YL, Liu W, Gao CX, Shang Z, Ning LJ, Liu X. CASP-1, -2 and -5 gene polymorphisms and cancer risk: A review and meta-analysis. Biomed Rep 2013;1:511-6. [PMID: 24648977 DOI: 10.3892/br.2013.98] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
35 Wang J, Gao J, Li Y, Zhao X, Gao W, Peng L, Yan D, Liu L, Li D, Wei L, Qi J, Zhou C. Functional polymorphisms in FAS and FASL contribute to risk of squamous cell carcinoma of the larynx and hypopharynx in a Chinese population. Gene 2013;524:193-6. [PMID: 23618817 DOI: 10.1016/j.gene.2013.04.034] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
36 Zamani AG, Barlas IO, Durakbasi-dursun G, Ural O, Erdal E, Yildirim MS. Evaluation of death pathway genes FAS and FASL polymorphisms in chronic HBV infection. Int J Immunogenet 2013;40:482-7. [DOI: 10.1111/iji.12056] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
37 Sezgin M, Barlas İÖ, Yıldır S, Türköz G, Ankaralı HÇ, Şahin G, Erdal ME. Apoptosis-related Fas and FasL gene polymorphisms' associations with knee osteoarthritis. Rheumatol Int 2013;33:2039-43. [PMID: 23392773 DOI: 10.1007/s00296-013-2688-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
38 Lin Y, Liu L, Zhang T, Liu J. Functional Investigation of Fas Ligand Expressions in Human Non-Small Cell Lung Cancer Cells and Its Clinical Implications. The Annals of Thoracic Surgery 2013;95:412-8. [DOI: 10.1016/j.athoracsur.2012.08.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
39 Hashemi M, Fazaeli A, Ghavami S, Eskandari-Nasab E, Arbabi F, Mashhadi MA, Taheri M, Chaabane W, Jain MV, Łos MJ. Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases. PLoS One 2013;8:e53075. [PMID: 23326385 DOI: 10.1371/journal.pone.0053075] [Cited by in Crossref: 50] [Cited by in F6Publishing: 56] [Article Influence: 5.6] [Reference Citation Analysis]
40 Karimi MY, Kapoor V, Sharma SC, Das SN. Genetic polymorphisms in FAS (CD95) and FAS ligand (CD178) promoters and risk of tobacco-related oral carcinoma: gene-gene interactions in high-risk Indians. Cancer Invest 2013;31:1-6. [PMID: 23153021 DOI: 10.3109/07357907.2012.743555] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
41 Jin G, Bae EY, Yang E, Lee EB, Lee WK, Choi JE, Jeon HS, Yoo SS, Lee SY, Lee J. A functional polymorphism on chromosome 15q25 associated with survival of early stage non-small-cell lung cancer. J Thorac Oncol. 2012;7:808-814. [PMID: 22722785 DOI: 10.1097/jto.0b013e31824c7d7c] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
42 Chen D, Ma T, Liu XW, Liu Z. CASP-8 -652 6N ins/del polymorphism and cancer risk: A literature-based systematic HuGE review and meta-analysis. Exp Ther Med 2012;4:762-70. [PMID: 23170140 DOI: 10.3892/etm.2012.661] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
43 Liu L, Wu J, Zhong R, Wu C, Zou L, Yang B, Chen W, Zhu B, Duan S, Yu D, Tan W, Nie S, Lin D, Miao X. Multi-loci analysis reveals the importance of genetic variations in sensitivity of platinum-based chemotherapy in non-small-cell lung cancer. Mol Carcinog 2013;52:923-31. [PMID: 22821704 DOI: 10.1002/mc.21942] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
44 Mahfoudh W, Bouaouina N, Gabbouj S, Chouchane L. FASL-844 T/C polymorphism: a biomarker of good prognosis of breast cancer in the Tunisian population. Hum Immunol 2012;73:932-8. [PMID: 22732091 DOI: 10.1016/j.humimm.2012.06.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
45 Nair RR, Khanna A, Singh K. Association of FAS -1377 G>A and FAS -670 A>G functional polymorphisms of FAS gene of cell death pathway with recurrent early pregnancy loss risk. J Reprod Immunol 2012;93:114-8. [PMID: 22386066 DOI: 10.1016/j.jri.2011.12.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
46 Tong N, Zhang L, Sheng X, Wang M, Zhang Z, Fang Y, Xue Y, Li J, Zhang Z. Functional polymorphisms in FAS, FASL and CASP8 genes and risk of childhood acute lymphoblastic leukemia: a case-control study. Leuk Lymphoma 2012;53:1360-6. [PMID: 22211869 DOI: 10.3109/10428194.2011.654117] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
47 Wang W, Zheng Z, Yu W, Lin H, Cui B, Cao F. Polymorphisms of the FAS and FASL genes and risk of breast cancer. Oncol Lett 2012;3:625-8. [PMID: 22740964 DOI: 10.3892/ol.2011.541] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
48 Bae EY, Lee EJ, Kang HG, Lee SY, Jin G, Lee WK, Choi JE, Jeon HS, Lim JO, Lee EB, Park JY. Polymorphisms in apoptosis-related genes and TP53 mutations in non-small cell lung cancer. J Korean Med Sci 2011;26:1527-30. [PMID: 22065914 DOI: 10.3346/jkms.2011.26.11.1527] [Reference Citation Analysis]
49 Kim MJ, Kang HG, Lee SY, Jeon HS, Lee WK, Park JY, Lee EB, Lee JH, Cha SI, Kim DS, Kim CH, Kam S, Jung TH, Park JY. AKT1 polymorphisms and survival of early stage non-small cell lung cancer. J Surg Oncol 2012;105:167-74. [PMID: 21842521 DOI: 10.1002/jso.22071] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
50 George GP, Mandal RK, Kesarwani P, Sankhwar SN, Mandhani A, Mittal RD. Polymorphisms and haplotypes in caspases 8 and 9 genes and risk for prostate cancer: a case-control study in cohort of North India. Urol Oncol 2012;30:781-9. [PMID: 21396853 DOI: 10.1016/j.urolonc.2010.08.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
51 Wei S, Niu J, Zhao H, Liu Z, Wang LE, Han Y, Chen WV, Amos CI, Rafnar T, Sulem P, Stefansson K, Landi MT, Caporaso NE, Albanes D, Thun MJ, McKay JD, Brennan P, Wang Y, Houlston RS, Spitz MR, Wei Q. Association of a novel functional promoter variant (rs2075533 C>T) in the apoptosis gene TNFSF8 with risk of lung cancer--a finding from Texas lung cancer genome-wide association study. Carcinogenesis 2011;32:507-15. [PMID: 21292647 DOI: 10.1093/carcin/bgr014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
52 Liu L, Wu C, Wang Y, Zhong R, Wang F, Zhang X, Duan S, Lou J, Yu D, Tan W, Yuan J, Wu T, Nie S, Miao X, Lin D. Association of candidate genetic variations with gastric cardia adenocarcinoma in Chinese population: a multiple interaction analysis. Carcinogenesis 2011;32:336-42. [PMID: 21148629 DOI: 10.1093/carcin/bgq264] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
53 Cao Y, Miao XP, Huang MY, Deng L, Lin DX, Zeng YX, Shao JY. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol Carcinog 2010;49:944-50. [PMID: 20842669 DOI: 10.1002/mc.20676] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
54 Kim HJ, Jin XM, Kim HN, Lee IK, Park KS, Park MR, Jo DY, Won JH, Kwak JY, Kim HJ, Choi JS, Juhng SW, Choi C. Fas and FasL polymorphisms are not associated with acute myeloid leukemia risk in Koreans. DNA Cell Biol 2010;29:619-24. [PMID: 20438363 DOI: 10.1089/dna.2010.1032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
55 Kita D, Hayashi Y, Watanabe T, Korshunov A, von Deimling A, Nakada M, Kasahara Y, Zen Y, Hamada J, Hayashi Y. Secondary anaplastic astrocytoma developing in a young adult with autoimmune lymphoproliferative syndrome (ALPS). Neuropathol Appl Neurobiol 2011;37:423-7. [PMID: 20846185 DOI: 10.1111/j.1365-2990.2010.01123.x] [Reference Citation Analysis]
56 Zhu J, Qin C, Wang M, Yan F, Ju X, Meng X, Ding Q, Li P, Yang J, Cao Q, Zhang Z, Yin C. Functional polymorphisms in cell death pathway genes and risk of renal cell carcinoma. Mol Carcinog 2010;49:810-7. [PMID: 20572163 DOI: 10.1002/mc.20656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.2] [Reference Citation Analysis]
57 Kim M, Kang H, Lee SY, Lee HC, Lee EB, Choi YY, Lee WK, Cho S, Jin G, Jheon H, Son JW, Lee M, Jung DK, Cha SI, Kim CH, Kang YM, Kam S, Jung TH, Jheon S, Park JY. Comprehensive analysis of DNA repair gene polymorphisms and survival in patients with early stage non-small-cell lung cancer. Cancer Science 2010;101:2436-42. [DOI: 10.1111/j.1349-7006.2010.01699.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
58 Wang LH, Ting SC, Chen CH, Tsai CC, Lung O, Liu TC, Lee CW, Wang YY, Tsai CL, Lin YC. Polymorphisms in the apoptosis-associated genes FAS and FASL and risk of oral cancer and malignant potential of oral premalignant lesions in a Taiwanese population. J Oral Pathol Med 2010;39:155-61. [PMID: 20359312 DOI: 10.1111/j.1600-0714.2009.00873.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
59 Shi C, Qian Y, Su J, Luo S, Gu J, You H, Cui Q, Lin Y, Dong M, Yu R. Genetic variation in the LMP/TAP gene and outcomes of hepatitis B virus infection in the Chinese population. Epidemiol Infect 2011;139:674-82. [DOI: 10.1017/s0950268810001299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
60 Lei D, Sturgis EM, Wang LE, Liu Z, Zafereo ME, Wei Q, Li G. FAS and FASLG genetic variants and risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 2010;19:1484-91. [PMID: 20501759 DOI: 10.1158/1055-9965.EPI-10-0030] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
61 Zhai R, Chen F, Liu G, Su L, Kulke MH, Asomaning K, Lin X, Heist RS, Nishioka NS, Sheu CC, Wain JC, Christiani DC. Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J Clin Oncol 2010;28:2445-51. [PMID: 20385987 DOI: 10.1200/JCO.2009.26.2790] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
62 Truong T, Sauter W, McKay JD, Hosgood HD 3rd, Gallagher C, Amos CI, Spitz M, Muscat J, Lazarus P, Illig T, Wichmann HE, Bickeböller H, Risch A, Dienemann H, Zhang ZF, Naeim BP, Yang P, Zienolddiny S, Haugen A, Le Marchand L, Hong YC, Kim JH, Duell EJ, Andrew AS, Kiyohara C, Shen H, Matsuo K, Suzuki T, Seow A, Ng DP, Lan Q, Zaridze D, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Constantinescu V, Bencko V, Foretova L, Janout V, Caporaso NE, Albanes D, Thun M, Landi MT, Trubicka J, Lener M, Lubinski J, Wang Y, Chabrier A, Boffetta P, Brennan P, Hung RJ; EPIC-lung. International Lung Cancer Consortium: coordinated association study of 10 potential lung cancer susceptibility variants. Carcinogenesis 2010;31:625-33. [PMID: 20106900 DOI: 10.1093/carcin/bgq001] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
63 Zhou RM, Wang N, Chen ZF, Duan YN, Sun DL, Li Y. Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma. J Gastroenterol Hepatol 2010;25:555-61. [PMID: 20074157 DOI: 10.1111/j.1440-1746.2009.06116.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
64 Chatterjee K, Engelmark M, Gyllensten U, Dandara C, van der Merwe L, Galal U, Hoffman M, Williamson AL. Fas and FasL gene polymorphisms are not associated with cervical cancer but differ among Black and Mixed-ancestry South Africans. BMC Res Notes 2009;2:238. [PMID: 19941645 DOI: 10.1186/1756-0500-2-238] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
65 Hrstka R, Coates PJ, Vojtesek B. Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med. 2009;13:440-453. [PMID: 19379143 DOI: 10.1111/j.1582-4934.2008.00634.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
66 Wang M, Wu D, Tan M, Gong W, Xue H, Shen H, Zhang Z. FAS and FAS ligand polymorphisms in the promoter regions and risk of gastric cancer in Southern China. Biochem Genet 2009;47:559-68. [PMID: 19565204 DOI: 10.1007/s10528-009-9264-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
67 Ji G, Gu A, Hu F, Wang S, Liang J, Xia Y, Lu C, Song L, Fu G, Wang X. Polymorphisms in cell death pathway genes are associated with altered sperm apoptosis and poor semen quality. Hum Reprod 2009;24:2439-46. [PMID: 19542541 DOI: 10.1093/humrep/dep223] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
68 Liu Y, Wen QJ, Yin Y, Lu XT, Pu SH, Tian HP, Lou YF, Tang YN, Jiang X, Lu GS, Zhang J. FASLG polymorphism is associated with cancer risk. Eur J Cancer 2009;45:2574-8. [PMID: 19403301 DOI: 10.1016/j.ejca.2009.04.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
69 Young RP, Hopkins RJ, Hay BA, Epton MJ, Mills GD, Black PN, Gardner HD, Sullivan R, Gamble GD. Lung cancer susceptibility model based on age, family history and genetic variants. PLoS One 2009;4:e5302. [PMID: 19390575 DOI: 10.1371/journal.pone.0005302] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
70 Zhang Z, Qiu L, Wang M, Tong N, Li J, Zhang Z. The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies. Eur J Hum Genet 2009;17:1294-303. [PMID: 19337311 DOI: 10.1038/ejhg.2009.45] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
71 Qiu LX, Shi J, Yuan H, Jiang X, Xue K, Pan HF, Li J, Zheng MH. FAS -1,377 G/A polymorphism is associated with cancer susceptibility: evidence from 10,564 cases and 12,075 controls. Hum Genet 2009;125:431-5. [PMID: 19225810 DOI: 10.1007/s00439-009-0639-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
72 Ulybina YM, Kuligina ES, Mitiushkina NV, Rozanov ME, Ivantsov AO, Ponomariova DN, Togo AV, Levchenko EV, Shutkin VA, Brenister SI, Devilee P, Zhivotovsky B, Hirvonen A, Imyanitov EN. Coding polymorphisms in Casp5, Casp8 and DR4 genes may play a role in predisposition to lung cancer. Cancer Lett 2009;278:183-91. [PMID: 19203830 DOI: 10.1016/j.canlet.2009.01.012] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
73 Zhang Z, Xue H, Gong W, Wang M, Yuan L, Han S, Zhang Z. FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case–control studies. Carcinogenesis 2009;30:487-93. [DOI: 10.1093/carcin/bgp016] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
74 Wang W, Lu N, Xia Y, Gu A, Wu B, Liang J, Zhang W, Wang Z, Su J, Wang X. FAS and FASLG polymorphisms and susceptibility to idiopathic azoospermia or severe oligozoospermia. Reproductive BioMedicine Online 2009;18:141-7. [DOI: 10.1016/s1472-6483(10)60436-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
75 Lee WK, Kim JS, Kang HG, Cha SI, Kim DS, Hyun DS, Kam S, Kim CH, Jung TH, Park JY. Polymorphisms in the Caspase7 gene and the risk of lung cancer. Lung Cancer 2009;65:19-24. [PMID: 19058873 DOI: 10.1016/j.lungcan.2008.10.022] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
76 Patra SK, Szyf M. DNA methylation-mediated nucleosome dynamics and oncogenic Ras signaling: insights from FAS, FAS ligand and RASSF1A. FEBS J. 2008;275:5217-5235. [PMID: 18803665 DOI: 10.1111/j.1742-4658.2008.06658.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
77 Ter-Minassian M, Zhai R, Asomaning K, Su L, Zhou W, Liu G, Heist RS, Lynch TJ, Wain JC, Lin X, De Vivo I, Christiani DC. Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis 2008;29:2147-52. [PMID: 18757527 DOI: 10.1093/carcin/bgn205] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 3.0] [Reference Citation Analysis]
78 Jang JS, Kim KM, Choi JE, Cha SI, Kim CH, Lee WK, Kam S, Jung TH, Park JY. Identification of polymorphisms in the Caspase-3 gene and their association with lung cancer risk. Mol Carcinog 2008;47:383-90. [PMID: 18058802 DOI: 10.1002/mc.20397] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
79 Tsuzaka K, Matsumoto Y, Sasaki Y, Abe T, Tsubota K, Takeuchi T. Down-regulation of Fas-ligand mRNA in Sjögren's syndrome patients with enlarged exocrine glands. Autoimmunity 2007;40:497-502. [PMID: 17966039 DOI: 10.1080/08916930701580320] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
80 Ho T, Li G, Zhao C, Zheng R, Wei Q, Sturgis EM. Fas single nucleotide polymorphisms and risk of thyroid and salivary gland carcinomas: A case-control analysis. Head Neck 2008;30:297-305. [DOI: 10.1002/hed.20699] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
81 Hancock DB, Martin ER, Li YJ, Scott WK. Methods for interaction analyses using family-based case-control data: conditional logistic regression versus generalized estimating equations. Genet Epidemiol 2007;31:883-93. [PMID: 17565751 DOI: 10.1002/gepi.20249] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
82 Patra SK. Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta. 2008;1785:182-206. [PMID: 18166162 DOI: 10.1016/j.bbcan.2007.11.002] [Cited by in Crossref: 45] [Cited by in F6Publishing: 142] [Article Influence: 3.0] [Reference Citation Analysis]
83 Koshkina NV, Kleinerman ES, Li G, Zhao CC, Wei Q, Sturgis EM. Exploratory Analysis of Fas Gene Polymorphisms in Pediatric Osteosarcoma Patients. Journal of Pediatric Hematology/Oncology 2007;29:815-21. [DOI: 10.1097/mph.0b013e3181581506] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
84 Zhang H, Sun XF, Synnerstad I, Rosdahl I. Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: a case-control analysis. Cancer J 2007;13:233-7. [PMID: 17762757 DOI: 10.1097/PPO.0b013e318046f214] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
85 Jung YJ, Kim YJ, Kim LH, Lee SO, Park BL, Shin HD, Lee HS. Putative association of Fas and FasL gene polymorphisms with clinical outcomes of hepatitis B virus infection. Intervirology. 2007;50:369-376. [PMID: 17938571 DOI: 10.1159/000109751] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
86 Gaddipati H, Herlyn M. Association of polymorphisms of FAS-1377, FAS-670, and FASL-844 genes with risk factors for cutaneous malignant melanoma. Cancer J 2007;13:226-8. [PMID: 17762755 DOI: 10.1097/PPO.0b013e31813fffdd] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
87 Lima L, Morais A, Lobo F, Calais-da-Silva FM, Calais-da-Silva FE, Medeiros R. Association between FAS polymorphism and prostate cancer development. Prostate Cancer Prostatic Dis 2008;11:94-8. [PMID: 17667965 DOI: 10.1038/sj.pcan.4501002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
88 Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, Guo Y, Yang M, Zhang X, Zhang Q, Zeng C, Lin D. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 2007;39:605-13. [DOI: 10.1038/ng2030] [Cited by in Crossref: 198] [Cited by in F6Publishing: 187] [Article Influence: 13.2] [Reference Citation Analysis]
89 Ivansson EL, Gustavsson IM, Magnusson JJ, Steiner LL, Magnusson PK, Erlich HA, Gyllensten UB. Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer. Int J Cancer 2007;121:2451-7. [DOI: 10.1002/ijc.22989] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 3.9] [Reference Citation Analysis]
90 Son JW, Kang HK, Chae MH, Choi JE, Park JM, Lee WK, Kim CH, Kim DS, Kam S, Kang YM, Park JY. Polymorphisms in the caspase-8 gene and the risk of lung cancer. Cancer Genet Cytogenet 2006;169:121-7. [PMID: 16938569 DOI: 10.1016/j.cancergencyto.2006.04.001] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 2.6] [Reference Citation Analysis]
91 Park SH, Choi JE, Kim EJ, Jang JS, Lee WK, Cha SI, Kim CH, Kam S, Kim DS, Park RW, Kim YC, Han SB, Jung TH, Park JY. Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population. Lung Cancer 2006;54:303-8. [PMID: 17014925 DOI: 10.1016/j.lungcan.2006.09.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
92 Park JY, Park JM, Jang JS, Choi JE, Kim KM, Cha SI, Kim CH, Kang YM, Lee WK, Kam S, Park RW, Kim IS, Lee JT, Jung TH. Caspase 9 promoter polymorphisms and risk of primary lung cancer. Hum Mol Genet 2006;15:1963-71. [PMID: 16687442 DOI: 10.1093/hmg/ddl119] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 4.3] [Reference Citation Analysis]
93 Li C, Larson D, Zhang Z, Liu Z, Strom SS, Gershenwald JE, Prieto VG, Lee JE, Ross MI, Mansfield PF, Cormier JN, Duvic M, Grimm EA, Wei Q. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenetics and Genomics 2006;16:253-63. [DOI: 10.1097/01.fpc.0000199501.54466.de] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
94 Li C, Wu W, Liu J, Qian L, Li A, Yang K, Wei Q, Zhou J, Zhang Z. Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case–control analysis. Pharmacogenetics and Genomics 2006;16:245-51. [DOI: 10.1097/01.fpc.0000194425.58511.a7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
95 Sun T, Zhou Y, Li H, Han X, Shi Y, Wang L, Miao X, Tan W, Zhao D, Zhang X, Guo Y, Lin D. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med 2005;202:967-74. [PMID: 16186185 DOI: 10.1084/jem.20050707] [Cited by in Crossref: 88] [Cited by in F6Publishing: 85] [Article Influence: 5.2] [Reference Citation Analysis]